Find clinical trials for Multiple Myeloma in New Haven, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Multiple Myeloma trials near New Haven, CT, USA:
a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...
Phase 1, Phase 2
•Stony Brook, New York, United States and 34 other locations
bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or sympto ...
Phase 2
•Stamford, Connecticut, United States and 5 other locations
(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...
Phase 2
•Stamford, Connecticut, United States and 48 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
•Valhalla, New York, United States and 222 other locations
(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...
Phase 3
•Fairfield, Connecticut, United States and 143 other locations
drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemothera...
Phase 1, Phase 2
•Stony Brook, New York, United States and 29 other locations
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...
Phase 3
•Bay Shore, New York, United States and 134 other locations
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....
Phase 1
•New Haven, Connecticut, United States and 18 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
•New Haven, Connecticut, United States and 285 other locations
antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratum ...
Phase 3
•Commack, New York, United States and 243 other locations
Clinical trials
Research sites
Resources
Legal